	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	204.96	257.88	510.31	520.86	499.52	543.53	625.26	285.67	14.41	13.48	11.84	13.54	11.69	6.66	7.11	8.81
Cost of Operating Revenue	108.48	129.59	188.23	242.82	241.29	235.16	241.07	120.68	5.80	4.38	4.55	6.91	7.48	7.16	7.16	-
Gross Profit	96.48	128.29	322.09	278.04	258.23	308.37	384.19	164.99	8.61	9.10	7.29	6.63	4.21	-0.50	-0.05	8.81
Gross Margin	47.1	49.7	63.1	53.4	51.7	56.7	61.4	57.8	59.8	67.5	61.5	49.0	36.0	-7.5	-0.6	100.0
Total Operating Expenses	180.79	208.72	299.86	372.90	415.23	434.72	448.38	310.75	134.08	97.48	138.17	145.51	146.13	178.02	296.36	381.47
Operating Profit	24.17	49.16	210.45	147.95	84.29	108.82	176.88	-25.08	-119.66	-84.00	-126.32	-131.97	-134.44	-171.37	-289.24	-372.66
Operating Margin	11.8	19.1	41.2	28.4	16.9	20.0	28.3	-8.8	-830.1	-623.2	-1,066.5	-974.7	-1,149.7	-2,574.7	-4,065.4	-4,228.1
Financing Income/(Expense) - Net	-9.20	-12.68	-7.49	3.43	13.16	13.57	18.28	24.95	12.97	5.81	0.58	7.46	20.76	6.07	5.35	-0.63
Profit before Taxes	9.14	32.85	202.74	151.55	97.58	123.07	195.53	0.16	-106.40	-77.47	-122.00	-118.27	-106.08	-160.75	-276.34	-352.44
Income Taxes	-5.22	2.01	58.58	42.80	25.74	35.88	71.84	24.06	-12.18	-5.32	-	-	-1.00	-	-	-
Profit after Tax	14.36	30.84	144.16	108.75	71.85	87.19	123.69	-23.90	-94.22	-72.15	-122.00	-118.27	-105.08	-160.75	-276.34	-352.44
PAT Margin	7.0	12.0	28.2	20.9	14.4	16.0	19.8	-8.4	-653.6	-535.3	-1,030.0	-873.5	-898.6	-2,415.1	-3,884.1	-3,998.7
EPS - Basic - ex Extraordinary Items	1.13	2.43	11.37	8.33	5.20	6.31	8.95	-1.73	-6.82	-5.22	-9.05	-6.63	-4.82	-7.37	-12.13	-14.77
EPS - Diluted - ex Extraordinary Items	1.13	2.43	11.37	8.33	5.20	6.31	8.95	-1.73	-6.82	-5.22	-9.05	-6.63	-4.82	-7.37	-12.13	-14.77
EBIT	24.17	49.16	210.45	147.95	84.29	108.82	176.88	-25.08	-119.66	-84.00	-126.32	-131.97	-134.44	-171.37	-289.24	-372.66
EBITDA	32.72	59.63	221.94	172.16	108.25	136.46	201.65	-10.89	-115.49	-79.65	-121.93	-125.43	-127.93	-165.55	-283.63	-366.26
EBITDA Margin	16.0	23.1	43.5	33.1	21.7	25.1	32.3	-3.8	-801.2	-591.0	-1,029.4	-926.4	-1,094.1	-2,487.3	-3,986.5	-4,155.5

Balance Sheet

Abridged

Understanding Balance Sheet

Suven Life Sciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	105	137	281	449	428	492	570	281	66	103	67	252	257	75	547
Long-Term Investments	0	0	0	-	0	0	0	-	-	-	-	100	-	-	-
Property Plant & Equipment - Net	156	171	192	279	312	314	330	22	25	26	41	37	28	59	76
Total Non-Current Assets	180	191	206	296	324	324	350	22	116	26	41	137	28	60	78
Total Assets	285	328	487	746	751	816	919	303	182	128	108	389	285	135	624
Total Current Liabilities	101	107	155	118	111	119	122	40	27	16	8	11	14	23	19
Long Term Debt	55	64	38	59	42	26	2	2	4	3	2	1	-	-	12
Total Non-Current Liabilities	57	66	67	63	46	30	29	24	12	4	4	2	1	2	14
Total Liabilities	157	173	222	182	156	149	151	63	38	20	12	14	15	25	33
Total Shareholders' Equity	128	154	264	564	595	667	768	240	144	108	96	375	270	110	591
Total Equity	128	154	264	564	595	667	768	240	144	108	96	375	270	110	591
Total Liabilities & Equity	285	328	487	746	751	816	919	303	182	128	108	389	285	135	624

Cash Flow

Abridged

Understanding Cash Flow Statement

Suven Life Sciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	19.20	37.56	173.27	137.82	78.96	96.27	158.57	-21.36	-104.72	-75.16	-122.89	-121.31	-106.09	-158.53	-278.85
Working Capital - Increase/(Decrease)	5.42	-18.74	-57.26	8.24	-14.36	7.90	-92.37	-32.98	-17.13	-14.70	-3.93	11.48	6.89	10.07	-18.33
Net CF from Operating Activities	24.62	18.82	116.01	146.06	64.60	104.18	66.20	-54.34	-121.85	-89.86	-126.82	-109.83	-99.20	-148.47	-297.17
Capital Expenditures - Net	27.27	20.04	37.88	118.25	57.86	30.53	41.77	39.50	2.39	6.30	19.77	2.89	-2.42	37.28	5.08
Net CF from Investing Activities	-32.70	-15.63	-37.98	-118.24	-41.61	-311.33	-1.50	36.95	133.00	48.86	-23.35	-254.23	78.01	149.27	-466.35
Dividends Paid - Cash - Total	3.39	4.07	4.10	34.17	39.83	12.73	22.98	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	0.20	-	200.00	-	-	-	-	-	36.92	147.64	397.40	-	-	755.98
Debt - LT & ST - Issuance/(Retirement) - Total	11.39	19.26	-26.50	17.94	-21.84	-9.38	-24.46	6.45	3.29	-1.25	-1.56	-1.60	-0.90	-0.71	-0.37
Net Cash Flow from Financing Activities	8.00	15.39	-30.60	183.77	-62.19	-24.70	-47.44	6.45	3.29	35.67	146.09	395.80	-0.90	-0.71	756.78
Free Cash Flow to Equity	8.75	18.04	51.63	45.75	-15.10	64.26	-0.03	-87.39	-120.94	-97.41	-148.14	-114.32	-97.68	-186.45	-302.63
Free Operating CF net dividend	-6.04	-5.32	74.03	-6.40	-33.09	60.91	1.43	-93.84	-124.23	-96.16	-146.59	-112.72	-	-185.74	-302.26
Free Operating CF	-2.65	-1.25	78.13	27.77	6.74	73.64	24.41	-93.84	-124.23	-96.16	-146.59	-112.72	-	-185.74	-302.26

Business Segment Analysis

FY End:

Mar 26

Suven Life Sciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Reasearch and Development (100.0%)₹ 5.08 Cr

Revenue / Sales

Reasearch and Development (100.0%)₹ 7.11 Cr

Assets

Reasearch and Development (100.0%)₹ 624.21 Cr

Operating Income

Reasearch and Development (100.0%)₹ -289.24 Cr

Regional Segment Analysis

FY End:

Mar 26

Suven Life Sciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

U.S.A (35.3%)₹ 2.51 CrIndia (30.3%)₹ 2.16 CrEurope (21.5%)₹ 1.53 CrOther (12.9%)₹ 0.92 Cr

Historical Segment Analysis

Track how Suven Life Sciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2025 Mar 31	2026 Mar 31
	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2025 Mar 31	2026 Mar 31
Reasearch and Development	-	-	-	-	-	-	-	-	-	2	6	20	3	37	5
Manufacturing	3	2	3	38	25	21	158	28	13	-	-	-	-	-	-
Research and Development	2	2	1	1	2	3	0	0	6	-	-	-	-	-	-
Services	-	0	34	0	2	0	0	0	6	-	-	-	-	-	-
Un allocated	-	0	0	0	0	0	0	0	2	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Suven Life Sciences Ltd.?

The latest trailing twelve month revenue of Suven Life Sciences Ltd. is ₹ 7.11 Cr, reflecting a 1-year growth of 6.89% and a 3-year CAGR of -19.30%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Suven Life Sciences Ltd.?

The latest trailing twelve month net profit (PAT) of Suven Life Sciences Ltd. is ₹ -276.34 Cr, with a 3-year earnings CAGR of -22.28%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Suven Life Sciences Ltd.?

The trailing twelve month EBITDA of Suven Life Sciences Ltd. is approximately ₹ -290.12 Cr (based on an operating margin of -4,077.70%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Suven Life Sciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Suven Life Sciences Ltd. is -12.13. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Suven Life Sciences Ltd.?

The debt-to-equity ratio of Suven Life Sciences Ltd. stands at 0.03. The interest coverage ratio is -1,934.11x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Suven Life Sciences Ltd.?

The estimated book value per share of Suven Life Sciences Ltd. is 20.93 (derived from a P/B ratio of 17.83 and market price of ₹ 373.15), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Suven Life Sciences Ltd.?

The trailing twelve month operating cash flow of Suven Life Sciences Ltd. is ₹ -297.55 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Suven Life Sciences Ltd. report consolidated or standalone financials?

Suven Life Sciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.